Daily variation of NTBC and its relation to succinylacetone in tyrosinemia type 1 patients comparing a single dose to two doses a day
Open Access
- 23 November 2017
- journal article
- research article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 41 (2) , 181-186
Abstract
Introduction: In hereditary tyrosinemia type 1 (HT1) patients, the dose of NTBC that leads to the absence of toxic metabolites such as succinylacetone (SA) is still unknown. Therefore, the aims of this study were to investigate the variation and concentrations of 2‐(2‐nitro‐4‐trifluormethyl‐benzyl)‐1,3‐cyclohexanedione (NTBC) during the day in relation to the detection of SA, while comparing different dosing regimens.Methods: All patients were treated with NTBC (mean 1.08 ± 0.34 mg/kg/day) and a low phenylalanine‐tyrosine diet. Thirteen patients received a single dose of NTBC and five patients twice daily. Home bloodspots were collected four times daily for three consecutive days measuring NTBC and SA concentrations. Statistical analyses were performed by using mixed model analyses and generalized linear mixed model analyses to study variation and differences in NTBC concentrations and the correlation with SA, respectively.Results: NTBC concentrations varied significantly during the day especially if NTBC was taken at breakfast only (p = 0.026), although no significant difference in NTBC concentrations between different dosing regimens could be found (p = 0.289). Momentary NTBC concentrations were negatively correlated with SA (p < 0.001). Quantitatively detectable SA was only found in subjects with once daily administration of NTBC and associated with momentary NTBC concentrations <44.3 μmol/l.Discussion: NTBC could be less stable than previously considered, thus dosing NTBC once daily and lower concentrations may be less adequate. Further research including more data is necessary to establish the optimal dosing of NTBC.Keywords
Funding Information
- Tyrosinemia Foundation (Stichting Joris)
This publication has 20 references indexed in Scilit:
- Recommendations for the management of tyrosinaemia type 1Orphanet Journal of Rare Diseases, 2013
- Single dose NTBC‐treatment of hereditary tyrosinemia type IJournal of Inherited Metabolic Disease, 2012
- Liquid chromatography tandem mass spectrometry method for the quantitation of NTBC (2-(nitro-4-trifluoromethylbenzoyl)1,3-cyclohexanedione) in plasma of tyrosinemia type 1 patientsJournal of Chromatography B, 2009
- Tyrosinemia type I treated by NTBC: How does AFP predict liver cancer?Molecular Genetics and Metabolism, 2006
- Analysis of succinylacetone, as a Girard T derivative, in urine and dried bloodspots by flow injection electrospray ionization tandem mass spectrometryRapid Communications in Mass Spectrometry, 2006
- The Pathophysiology and Treatment of Hereditary Tyrosinemia Type 1Seminars in Liver Disease, 2001
- Pharmacokinetics and pharmacodynamics of NTBC (2‐(2‐nitro‐4‐fluoromethylbenzoyl)‐1,3‐cyclohexanedione) and mesotrione, inhibitors of 4‐hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteersBritish Journal of Clinical Pharmacology, 2001
- Tyrosinemia: A ReviewPediatric and Developmental Pathology, 2001
- The Mutagenicity of the Tyrosine Metabolite, Fumarylacetoacetate, Is Enhanced by Glutathione DepletionBiochemical and Biophysical Research Communications, 1997
- Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenaseThe Lancet, 1992